Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE-E: Cannabidiol in Refractory Epileptic Encephalopathy
NCT03024827Phase 1Unknown
- Sponsor
- University of Saskatchewan
- Start
- Apr 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CanniMed 1:20 in epileptic encephalopathy, sponsored by University of Saskatchewan. Primary endpoints: Heart Rate up to 6 months, Blood Pressure up to 6 months and 15 more. Status: unknown.
02
Drugs
CanniMed 1:20
03
Conditions
epileptic encephalopathy
Beyond the preview
Go deeper on NCT03024827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024827.